# Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

> **NCT01478048** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 185 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Elotuzumab
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone
- **DRUG:** Dexamethasone
- **DRUG:** Dexamethasone
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01478048
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-30
- **Primary completion:** 2014-05-30
- **Final completion:** 2017-04-21
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2018-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01478048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01478048, "Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01478048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*